iwCLL 2023 | Prevention of TLS with venetoclax-based regimens
Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, discusses the prevention of tumor lysis syndrome (TLS) in chronic lymphocytic leukemia (CLL) patients treated with a venetoclax-based regimen. Dr Scarfò assures that risk of TLS is low as a result of the ramp-up phase during initiation of venetoclax treatment, in which dosage is initially very low (20 mg) before being gradually increased up to the full dose (400 mg). Prevention strategies, including hydration of the patient and checking lab tests frequently, should be put into place to mitigate any residual risk of TLS. This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory board: AbbVie, AstraZeneca, BeiGene, Janssen, Lilly
Speaker bureau: Octapharma
